Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own1.00% Shs Outstand177.74M Perf Week-7.58%
Market Cap3.86B Forward P/E- EPS next Y-0.92 Insider Trans58.68% Shs Float164.32M Perf Month-14.57%
Income-210.10M PEG- EPS next Q-0.22 Inst Own73.50% Short Float10.32% Perf Quarter11.23%
Sales2.40M P/S1607.07 EPS this Y-135.30% Inst Trans3.39% Short Ratio6.66 Perf Half Y35.63%
Book/sh0.44 P/B49.32 EPS next Y27.00% ROA-98.60% Target Price36.00 Perf Year169.90%
Cash/sh2.02 P/C10.75 EPS next 5Y- ROE- 52W Range7.17 - 27.33 Perf YTD34.28%
Dividend- P/FCF- EPS past 5Y-44.67% ROI-200.90% 52W High-20.60% Beta1.74
Dividend %- Quick Ratio3.90 Sales past 5Y-37.60% Gross Margin72.70% 52W Low202.65% ATR0.94
Employees138 Current Ratio3.90 Sales Q/Q-61.50% Oper. Margin- RSI (14)32.38 Volatility4.43% 4.33%
OptionableYes Debt/Eq2.78 EPS Q/Q61.10% Profit Margin- Rel Volume0.70 Prev Close22.47
ShortableYes LT Debt/Eq2.78 EarningsAug 15 Payout- Avg Volume2.55M Price21.70
Recom1.50 SMA20-9.65% SMA50-10.63% SMA20022.04% Volume1,783,544 Change-3.43%
Jun-07-18Initiated B. Riley FBR, Inc. Buy $53
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Jul-29-15Downgrade Jefferies Buy → Hold
Aug-27-14Downgrade R. F. Lafferty Buy → Neutral $4
Jan-08-14Initiated Chardan Capital Markets Buy $9
Oct-02-13Reiterated Oppenheimer Outperform $6 → $8
Sep-10-13Initiated R. F. Lafferty Buy $8
Jun-03-13Initiated WallachBeth Buy $6
Aug-31-11Initiated Summer Street Research Buy $8
Jul-28-11Initiated Summer Street Research Buy $8
Jul-13-11Resumed Brean Murray Buy $8
May-17-11Initiated Oppenheimer Outperform $6
Feb-23-11Initiated Wedbush Outperform $6
Jul-03-07Initiated Brean Murray Buy $8
Feb-20-07Initiated Lazard Capital Buy $6
Aug-13-18 08:00AM  3 Biotech Stock Favorites to Bet on Today: Top Analysts TheStreet.com
Aug-10-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph Lauren, Alliant Energy, TreeHouse Foods, and Lincoln National New Research Emphasizes Economic Growth GlobeNewswire
Jul-30-18 08:00AM  Immunomedics Announces Multiple Clinical and Preclinical Collaborations With Prominent Cancer Research Institutions GlobeNewswire
Jul-23-18 08:00AM  Immunomedics Announces Clinical Collaboration With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers GlobeNewswire
Jul-18-18 08:00AM  FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer GlobeNewswire
Jul-11-18 07:35AM  Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks ACCESSWIRE
Jun-27-18 10:42AM  How Financially Strong Is Immunomedics Inc (NASDAQ:IMMU)? Simply Wall St.
Jun-21-18 04:42PM  [$$] Immunomedics Chairman Buys $19M More in Stock Barrons.com
08:20AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE
Jun-15-18 11:39AM  Immunomedics Announces Closing of Public Offering of Common Stock GlobeNewswire
Jun-13-18 08:00AM  Immunomedics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jun-12-18 02:30PM  The Charts of Immunomedics Look Very Bullish Now TheStreet.com
08:47AM  Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate Benzinga
Jun-11-18 04:13PM  Immunomedics Announces Proposed Public Offering of Common Stock GlobeNewswire
03:48PM  After-hours buzz: RH, PLAY and more CNBC
Jun-05-18 08:49AM  Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Genomic Health and Immunomedics ACCESSWIRE
Jun-04-18 04:33PM  Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today Motley Fool +10.26%
04:32PM  Why A Tie-Up With Clovis Helped This Biotech Spike To An 18-Year High Investor's Business Daily
03:20PM  Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today Motley Fool
01:18PM  5 Biotech Stocks Moving On ASCO Presentations Benzinga
08:00AM  Immunomedics Provides Business Update at the ASCO 2018 Investor Event GlobeNewswire
Jun-03-18 08:00PM  Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers GlobeNewswire
10:15AM  Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer GlobeNewswire
Jun-01-18 08:00AM  Immunomedics Announces Pivotal Study of Sacituzumab Govitecan in Patients With Locally Advanced or Metastatic Urothelial Cancer GlobeNewswire
May-30-18 08:00AM  Immunomedics to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-21-18 08:00AM  Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration GlobeNewswire
May-18-18 04:03AM  Edited Transcript of IMMU earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-17-18 12:43PM  Immunomedics Inc (NASDAQ:IMMU): Time For A Financial Health Check Simply Wall St. +7.12%
08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and Rite Aid ACCESSWIRE
May-16-18 05:01PM  Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer GlobeNewswire
May-09-18 04:24PM  Immunomedics: Fiscal 3Q Earnings Snapshot Associated Press
04:00PM  Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
07:30AM  Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics  Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-02-18 12:01PM  Harry Boxers four biotech stocks to watch today MarketWatch
08:00AM  Immunomedics to Report Third Quarter Fiscal 2018 Results and Host Conference Call and Webcast on May 9, 2018 GlobeNewswire
May-01-18 08:45AM  Immunomedics (IMMU) in Focus: Stock Moves 7.9% Higher Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics and Immunomedics ACCESSWIRE
Apr-25-18 12:15PM  Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-17-18 10:21AM  When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable? Simply Wall St.
Apr-13-18 08:20AM  Todays Research Reports on Trending Tickers: Exact Sciences and Immunomedics ACCESSWIRE
Apr-11-18 08:30AM  Todays Research Reports on Trending Tickers: Neuralstem and Immunomedics ACCESSWIRE
Apr-09-18 08:00AM  Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer GlobeNewswire
Mar-27-18 08:25AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE
Mar-05-18 08:00AM  Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-26-18 06:06PM  Edited Transcript of IMMU earnings conference call or presentation 8-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Feb-15-18 08:00AM  Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
07:30AM  Fennec Pharma (FENC): The Most Likely Acquisition Target in Healthcare with 200-300% Upside? ACCESSWIRE
Feb-14-18 07:30AM  Blog Exposure - FDA Accepts Amicus Therapeutics NDA for Migalastat for Treatment of Fabry Disease ACCESSWIRE
Feb-13-18 03:49PM  8 Companies That Could Disappear by 2019 InvestorPlace
Feb-09-18 05:01AM  Immunomedics reports 2Q loss Associated Press
Feb-08-18 04:15PM  Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
Feb-06-18 08:00AM  Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018 GlobeNewswire
Jan-31-18 08:20AM  New Research: Key Drivers of Growth for Cavco Industries, National Commerce, The Providence Service, Cisco, Immunomedics, and Emergent Biosolutions Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-17-18 07:00AM  Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock InvestorPlace
Jan-11-18 08:00AM  Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer GlobeNewswire
Jan-10-18 08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-08-18 08:30AM  Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million GlobeNewswire
Jan-04-18 08:45AM  Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:34AM  Harry Boxer: These two marijuana stocks are climbing higher MarketWatch
Dec-22-17 11:41AM  ETFs with exposure to Immunomedics, Inc. : December 22, 2017 Capital Cube +6.08%
Dec-21-17 12:23PM  BlackBerry Among Four Stocks Breaking Out Forbes
Dec-13-17 07:02AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-11-17 01:59PM  ETFs with exposure to Immunomedics, Inc. : December 11, 2017 Capital Cube
Dec-08-17 01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace
07:45AM  Immunomedics' Data Is Good News for Seattle Genetics, Too Motley Fool
07:16AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017 Capital Cube
Dec-07-17 08:10AM  Todays Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals ACCESSWIRE +16.16%
Dec-06-17 03:58PM  Why Immunomedics, Inc. Is Soaring Today Motley Fool +13.00%
12:10PM  Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) GlobeNewswire
Nov-30-17 02:00PM  ETFs with exposure to Immunomedics, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:04AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017 Capital Cube
Nov-28-17 08:05AM  Immunomedics, Full Study Data to be Presented December 6, 2017, BLA Application as Early as 1Q18 ACCESSWIRE
Nov-27-17 08:05AM  Analysis: Positioning to Benefit within Aradigm, General Motors, AT&T, Denbury Resources, Novavax, and Immunomedics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-20-17 07:40AM  Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE
Nov-16-17 08:43AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks +8.11%
Nov-15-17 08:38AM  Immunomedics (IMMU) Jumps: Stock Rises 5.4% Zacks +5.31%
Nov-14-17 04:07PM  Edited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMT Thomson Reuters StreetEvents +5.40%
12:44PM  Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract SmarterAnalyst
Nov-13-17 04:30PM  Why Sears Holdings, Immunomedics, and J.C. Penney Slumped Today Motley Fool -19.35%
09:30AM  Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium GlobeNewswire
07:24AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017 Capital Cube
Nov-10-17 03:02PM  Why Immunomedics, Inc. Jumped Higher Today Motley Fool +18.77%
08:20AM  Todays Research Reports on Trending Tickers: Endo International and Immunomedics ACCESSWIRE
Nov-09-17 05:21PM  Immunomedics reports 1Q loss Associated Press
04:10PM  Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
04:05PM  Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth GlobeNewswire
01:00PM  Immunomedics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 08:00AM  Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017 GlobeNewswire +6.82%
Oct-31-17 12:13PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : October 31, 2017 Capital Cube -5.13%
11:42AM  ETFs with exposure to Immunomedics, Inc. : October 31, 2017 Capital Cube
Oct-30-17 08:11AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : October 30, 2017 Capital Cube
Oct-27-17 09:35AM  Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers TheStreet.com +6.18%
Oct-23-17 08:37AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks
Oct-05-17 12:21PM  Edited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT Thomson Reuters StreetEvents -8.50%
Oct-03-17 11:19AM  ETFs with exposure to Immunomedics, Inc. : October 3, 2017 Capital Cube
Sep-15-17 04:30PM  Why Carnival, Immunomedics, and Fitbit Slumped Today Motley Fool
08:00AM  Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock GlobeNewswire
Sep-11-17 09:00AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks +5.17%
07:00AM  Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer GlobeNewswire
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer; and a collaboration agreement with Yale Cancer Center to evaluate its ADC product as a single agent in two phase II studies in patients with persistent or recurrent endometrial and cervical cancers. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
venBio Select Advisor LLCDirectorJun 15Buy24.00575,00013,800,00017,514,461Jun 15 02:02 PM
venBio Select Advisor LLCDirectorJun 15Buy23.39200,0004,678,00017,714,461Jun 19 04:05 PM
GOLDENBERG DAVID MDirectorMar 07Sale17.6840,000707,0005,613,252Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorMar 07Sale17.5020,000350,0001,774,285Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorMar 05Sale17.2440,000689,4005,653,252Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorFeb 28Sale17.0917,729302,9895,693,252Mar 12 08:32 PM
MARKISON BRIAN ADirectorNov 20Option Exercise3.1615,00047,40099,178Nov 21 05:00 PM
MARKISON BRIAN ADirectorNov 20Sale11.898,39099,72490,788Nov 21 05:00 PM
venBio Select Advisor LLCDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 15 05:48 PM
venBio Select Advisor LLCDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 15 05:48 PM
GOLDENBERG CYNTHIA LDirectorSep 01Sale12.9010,000129,000778,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksSep 01Sale12.9010,000129,0003,395,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 31Sale12.3810,000123,750788,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksAug 31Sale12.3810,000123,7503,405,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 28Sale11.5215,000172,841798,219Aug 28 08:54 PM
GOLDENBERG DAVID MSee RemarksAug 28Sale11.5610,000115,5913,415,578Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 24Sale10.2425,000256,105813,219Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 23Sale9.5010,00095,000838,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 23Sale9.5010,00095,0003,455,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 22Sale9.5010,00095,000848,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 22Sale9.5010,00095,0003,465,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 21Sale8.9720,000179,426858,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 21Sale8.9720,000179,4263,475,578Aug 23 09:00 PM